BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss
By Sydney Price · June 9, 2026, 4:52 PM EDT
Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical...
To view the full article, register now.